LinkedIn·Monday, 24 August 2026·1d ago
83% of sites improved trial quality when central statistical monitoring was applied. Only 56% improved without it. In the Summer issue of…
CluePoints
15,611 followers
83% of sites improved trial quality when central statistical monitoring was applied. Only 56% improved without it.
In the Summer issue of International Clinical Trials, CluePoints' Laura Trotta breaks down how advanced analytics move risk detection earlier, catching signals traditional monitoring misses.
From CSM flagging under-reported adverse events to data quality assessment surfacing a problem site eight months before the study team spotted it, the case for early detection is getting harder to ignore.
She also looks at where LLMs and agent-based systems fit, adding context to statistical signals rather than replacing them.
Read Laura's article in the Summer issue of ICT, pages 132-134: https://hubs.ly/Q04t-25d0
#ClinicalTrials #RBQM #ClinicalData #CentralStatisticalMonitoring #DataQuality
♥ 11↻ 1
View on LinkedIn Cross-referenced
Related on the wire
The RBQMLive 2026 agenda is live. Six years in, and the conversation has moved from "should we do RBQM" to "how do we prove it works." That…
We’re bringing the launch to the rooftop. 🎉 Join CluePoints at Urban Oak Rooftop Bar on Tuesday, September 15, as we celebrate the launch…
We know RBQM improves oversight. But what's it actually worth? In a new Q&A with ACRP, Sylviane de Viron (CluePoints) and Abigail Dirks, MS…
Are you ready to make the business case for RBQM? Join us for our upcoming webinar, where experts from CluePoints and the Tufts Center for…
The CRA role isn't shrinking. It's being elevated. For years, the job meant high-volume source data verification and box-checking against…
Real-world data is only as valuable as it is trustworthy. In her latest piece for PharmaLive, CluePoints Senior Strategic Consultant Sophie…